Malarial Vaccines Utilizing Antigen/Adjuvant Display on Viral-Like Particles

Award Information
Agency:
Department of Defense
Amount:
$629,510.00
Program:
SBIR
Contract:
W81XWH-10-C-0005
Solitcitation Year:
2009
Solicitation Number:
2009.2
Branch:
Army
Award Year:
2011
Phase:
Phase II
Agency Tracking Number:
A2-4234
Solicitation Topic Code:
A09-107
Small Business Information
Agave BioSystems, Inc.
P.O. Box 100, Ithaca, NY, -
Hubzone Owned:
Y
Woman Owned:
N
Socially and Economically Disadvantaged:
Y
Duns:
022552900
Principal Investigator
 Mehran Pazirandeh
 Staff Scientist
 (607) 272-0002
 mehranp@agavebio.com
Business Contact
 Noe Salazar
Title: President
Phone: (512) 373-8601
Email: nsalazar@agavebio.com
Research Institution
 Stub
Abstract
Recent studies have suggested the potential of improved malarial vaccines by use of the viral-like particle (VLP)-linked immunogen approach. The VLP technology is being utilized for the development of vaccines for a variety of diseases. Agave BioSystems is creating a novel platform for development of malarial vaccines consisting of a VLP displayed malarial antigen/adjuvant based on the Norwalk virus (NV) capsid protein. The VLP will be engineered to express a candidate antigen in combination with a peptide adjuvant. These VLPs will be characterized, purified and delivered for testing of efficacy to stimulate cellular and humoral immune responses.In the Phase I, Agave BioSystems successfully demonstrated proof-of concept for this novel platform.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government